3 results about "Ziconotide" patented technology

The invention provides a ziconotide nasal-brain delivery preparation which is high in brain targeting, safe and noninvasive and directly enters the brain through nasal administration. The nasal-brain delivery preparation comprises an active component ziconotide and an absorption enhancer, wherein the absorption enhancer is selected from one or more of dodecyl-beta-D-maltoside (DDM), menthol, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), sodium glycocholate (SGC) and related derivatives thereof. The absorption enhancer with a specific type and content and the ziconotide cooperate and act together, so that the ziconotide bypasses a blood brain barrier, enters the brain through a nasal olfactory mucous membrane, forms a medicine storage bank in an olfactory bulb, is slowly released to the brain and keeps a long-term medicine effect, and therefore, a traditional ziconotide intrathecal administration mode is abandoned; the ziconotide nasal-brain administration mode is created, and the ziconotide nasal-brain administration method is a new-generation therapy for pain diseases related to the central nervous system.

The invention discloses a ziconotide-loaded PLGA (poly (lactic-co-glycolic acid)) sustained-release microsphere as well as a preparation method and application thereof. The PLGA microspheres are mainly prepared from a polylactic acid-glycolic acid copolymer (PLGA), ziconotide and trehalose; the PLGA microspheres are prepared from the following components in percentage by mass: 85.2 to 95.6 percent of PLGA, 4.4 to 8.2 percent of ziconotide and 0 to 7.4 percent of trehalose, ziconotide medicine is uniformly dispersed in PLGA, microspheres are prepared by adopting a double-emulsification method, and stable medicine carrying microspheres are formed. The PLGA microspheres prepared by the invention can realize long-time slow release of ziconotide, significantly prolong the drug effect maintenance time, and show relatively low toxic and side effects in vivo; by means of controllable degradation of the PLGA material, ziconotide can be continuously released in vivo, the bioavailability of the medicine is improved, the compliance burden of a patient is reduced, the defects of an existing ziconotide administration mode are overcome, and an efficient, safe and sustainable slow-release treatment scheme is provided.

The invention relates to a Ziconotide temperature-sensitive nasal spray, which comprises a solvent, and Ziconotide, a first matrix, a second matrix, an absorption enhancer, a pH buffer system and a polypeptide stabilizer dispersed in the solvent, the first matrix is poloxamer 407, and the second matrix is poloxamer 188; the temperature-sensitive nasal spray comprises the following components in percentage by mass: 5%-20% of the first substrate, 0-5% of the second substrate, 0.01%-10% of the absorption enhancer, and the balance of the temperature-sensitive nasal spray, the pH buffer system is an acetic acid-acetate system or a lactic acid-lactate system. The ziconotide temperature-sensitive nasal spray can form a good spray form through a nasal spray device, the viscosity has a temperature-sensitive characteristic, and the ziconotide temperature-sensitive nasal spray is not easy to lose and has good stability.